《DPI:2023年现代化临床前和临床优化技术研究报告 (英文版)(44页).pdf》由会员分享,可在线阅读,更多相关《DPI:2023年现代化临床前和临床优化技术研究报告 (英文版)(44页).pdf(44页珍藏版)》请在三个皮匠报告上搜索。
1、Modern Technologiesfor Preclinical and ClinicalOptimisationwww.deep-pharma.techRelying on various research methods and analytics techniques,the analysis provides a comprehensive overview of the Preclinical and Clinical Trials Industry.This approach has certain limitations,especially when using publi
2、cly available data sources and conducting the secondary research.DPI is not responsible for the quality of the secondary data presented herein;however,we do our best to eliminate the said risks using different analytics techniques and cross-checking data.Please note that we did not deliberately excl
3、ude certain companies from our analysis.Nor was it due to the data-filtering method used or difficulties encountered.The main reason for their noninclusion was incomplete or missing information in the available sources.Report ApproachIndustry-Specialised Databases Data SourcesMedia Overview(Articles
4、 and Press Releases)Industry Reports and ReviewsPublicly Available Sources(Websites)DescriptiveAnalysisComparative AnalysisQualitative Data CollectionMixed Data ResearchData TriangulationData FilteringApplied Research and Analytics MethodsDatabase70Clinical Trials165Companies260InvestorsThe database
5、 was formed based on:the identification of companies that conduct or have conducted clinical or preclinical research of drugs the identification of companies that research or develops biomarkersDeep Pharma Intelligence2Market Size OverviewDeep Pharma Intelligence3Market Size GrowthCumulative Market
6、SizeMarket Size per YearMarket Size in$BYearTechnologies for preclinical and clinical optimization are becoming increasingly popular over the last few years.More and more companies specialising in the development of technologies for preclinical and clinical optimization are opening every year,and ev
7、en more companies are starting to implement these technologies in their R&D.In 2021,the market size of organoids,organ-on-a-chip,microfluidics,and lab automation technologies was estimated at$2.98 billion,and it will reach$3.68 billion in 2022.Considering this tendency,it is reasonable to say that p
8、reclinical and clinical optimization technologies start forming separate branches of industry.$3.68B$2.98B$2.01B$1.70B$1.53B$1.30B$1.25B$1.1B$0.81B$0.74B$0.1B$0.06B$0.02BCompanies 165 Investors 260 View More:deep-pharma.techCompaniesInvestorsOrganoidsLab AutomationOrgan-on-a-chipMicrofluidicsPreclin
9、ical and Clinical OptimisationDeep Pharma Intelligence5To maximise effects and lower costs for both new and existing treatments,Personalised Medicine is receiving a lot of attention in drug development today.Thus far,drugs have often been approved based on their safety and effectiveness in a variety
10、 of patients.The goal of Personalised Medicine is to create patient-tailored treatment plans by accounting for individual variability in medication response.It is the antithesis of this one drug fits all approach.Particularly,with regard to ex vivo treatment response prediction and associated medica
11、tion dose optimisation,patient-and disease-specific drug testing systems based on current advancements in stem cell,organoid,and organ-on-a-chip technology would be a great value.In this report,we are focusing on 3D human(multi)cellular assays,including organoids and organ-on-a-chip models,as well a
12、s on technologies that potentially can be used for their development,which includes microfluidics and lab automation.2D Cultures3D Cultures3D MicrophysiologyIn vitro Diseases ModellingIn vitro Drug DevelopmentSources:Berlo et al(2021).Current Opinion in Toxicology.Introduction:Innovative in Vitro Mo
13、delsIntroduction:Innovative in Vitro Models2D Models(Cell Culture)3D Models(Organoid)Microfluidic chip(Organ-on-a-Chip)3D cell culture is a culture environment that allows cells to grow and interact with the surrounding extracellular frameworks in three dimensions.Organoid is three-dimensional(3D)ce
14、ll structures that contain a multitude of organ-specific cells formed by self-organisation and differentiation of stem cells.Organoids are better at representing cellular environments found in vivo than conventional two-dimensional cell cultures.Organ-on-a-chip is a form of an artificial organ that
15、simulates the functions,mechanics,and physiological responses of an entire organ or organ system using a multichannel 3D microfluidic cell culture integrated circuit(chip).The chips are lined with living human cells,and their tiny fluidic channels reproduce blood and/or airflow similar to those in t
16、he human body.Their flexibility allows the chips to recreate breathing motion or undergo muscle contractions.Two-dimensional(2D)cell culture is performed on a flat substrate such as a petri dish.In this method,cell growth and division take place in a single plane.The cells are placed onto a coated s
17、urface to help them adhere and proliferate.It is a stable,successful,and well-established technique used in all types of in vitro research studies.Cells are easy to observe and measure in 2D culture.The downside is that it does not represent a real cell environment.In addition,there are a few issues
18、 caused by the expansion of cells and growth media.Deep Pharma Intelligence6Historical Overview of in Vitro Models DevelopmentDeep Pharma IntelligenceSources:Corro et al(2020).American Journal of Cell Physiology.71907Sponge cells self-organised to regenerate the whole organism1944Dissociation-reaggr
19、egation experiments with dissociated amphibian pronephros1947First transistor invented19601961Dissociation-reaggregation experiments with several organs from embryonic chickDifferentiation of embryoid bodies in vitro1979First commercial photolithography and microscale chromatography19873D organoid c
20、ulture of epithelium1993First 3D printer works1998Microfluidic device in PDMS2006iPSCs from mouse fibroblastsOrgan-on-a-chip technology20083D cerebral cortex tissue from ESCs3D printing applied to microfluidics2009Embryonic stem cell line established from human blastocystsGut organoids2010Gastric or
21、ganoidsTowards human-on-a-chip2012Retinal organoids from hPSCS2014Cerebral organoids from hPSCs2015Mammary gland,fallopian tube,hippocampal organoids2020Snake venom gland organoids What Can in Vitro Models Be Used for?Deep Pharma Intelligence8Organ replacement in regenerative medicineDrug toxicity t
22、estingEfficacy evaluation in preclinical developmentDevelopmental biology studies Discovering treatment options in precision medicine Disease models to study pathophysiologyIn vitro models are the starting point in biological and medical research.With scientific progress and the emergence of differe
23、nt in vitro models,knowledge of the entire organisms behaviour is growing.Since these cells and microorganisms are isolated from their natural environment,these models may not completely or precisely predict the effects on the entire organism,but they can open a lot of possibilities for medicine and
24、 drug discovery.In vitro models can be used in medicine to develop models of different diseases and study pathophysiology or to develop organs for replacement.In the drug development process,these models are used for testing drug toxicity and for evaluation of drug efficacy in preclinical studies.Wi
25、th the availability of in vitro models,personalised drug testing in the laboratory has become within reach.Fields of UsageBenefits of in Vitro Models:Financial ReasonPreclinical Discovery and testingPhase IPhase IIPhase IIIMarket#Of Candidate Compounds#Of Candidate Compounds w/Organoids3-6 Years6-7
26、Years0.5-2 YearsDevelopmental CostDevelopmental Cost w/OrganoidsCandidate Compounds250,00-500,00025051Faster Discovery w/OrganoidsOverall Cost$2.6BReduced Cost w/Organoids1 Approved New DrugDeep Pharma IntelligenceSources:Devarasetty et al(2018).BioDrugs.9The potential impact of organoid and orphan-
27、on-a-chip models on the drug discovery pipeline is a primary driver for their development and application.The 3D culture modalities are significantly more predictive and informative.Integration of physiologically relevant 3D organoid models could improve the drug development pipeline by eliminating
28、toxic or ineffective compounds in preclinical testing.Pharmaceutical development is mostly cost-driven by Phase IIII clinical trials.Organoids decrease the number of unsuccessful compounds that reach this stage,reducing cost and increasing the number of approved medications.This graph demonstrates d
29、rug development costs and candidates vs.time,with and without organoids.Benefits of in Vitro Models:Biological Reason Animal Model2D Cell Culture3D Cell CultureHuman OrganoidOrgan-on-a-ChipBiobankingVascularisationand immune systemHeterogeneityHigh-throughput screeningModeling for human physiologyMo
30、deling cellular/mechanical communicationsModeling patient-derived organoidsDeep Pharma IntelligenceSources:Heydari et al(2021).Bio-Design and Manufacturing.10The immensely complex processes of the human body cannot be accurately modeled by in vivo animal models,and there is growing concern regarding
31、 the morality of animal research.A system like an in vitro 2D cell culture model is frequently employed since it is reasonably priced,simple to use,and capable of gathering a lot of reference data.These models,however,are devoid of an actual extracellular physiological context.Organoids and organ-on
32、-a-chip technologies have enormous advantages compared to 2D cultures and animal models,which make them a practical platform for different experiments,modeling diseases,and high-throughput screening.In a culture dish,patient-derived organoids can serve as models of human disease.The development of n
33、umerous organoids and organ-on-a-chips for drug screening and testing has increased international competition for patents.Longevity.InternationalOrganoidsTypes of Organoids Deep Pharma Intelligence12Organoids can be divided into two categories based on the stem cells used.The first type is formed fr
34、om pluripotent stem cells(PSCs),which also include embryonic stem cells(ESCs)and induced pluripotent stem cells(iPSCs).The second type is derived from adult stem cells(ASCs)that are specialised for particular organs.Organoids such as the colon,intestine,liver,prostate,pancreas,fallopian tube,stomach
35、,tongue,and endometrial can all be grown from human ASCs.Organoids of the digestive system,liver,lungs,kidneys,pancreas,stomach,and retina can all be cultured from PSCs.The cerebral,optic cup,and renal organoids serve as examples of how alterations to the aforementioned methodology can be used to cu
36、lture PSC-derived organoids that are not produced from endoderm.Both cell types possess the distinct ability to self-renew and SC-derived organoids typically recapitulate early stages of cellular proliferation that can be used to study development and foetal infections,for example.KidneyBrainLiverIn
37、ner earThyroidOpticSmall intestineLungPancreasLargeintestineStomachBladderOvaryBreastProstateTongueSpleenPluripotent Stem Cells(PSCs)Adult Stem Cells(ASCs)Embryonic Stem Cells(ESCs)Induced Pluripotent Stem Cells(IPCs)Adult Stem Cells(ASCs)Process of Organoid DevelopmentDeep Pharma Intelligence13ASC-
38、derived organoids are grown from healthy or tumorous tissue biopsies.A single-cell suspension made from processed tissues is then immediately enmeshed in an extracellular matrix.Until organoids have developed,media containing a variety of growth agents,which vary depending on the tissue being grown,
39、is continuously added to.ASC-derived organoids can provide complementary adult epithelium to investigate mature tissue responses to pathogenic attacks or medications.PSC-derived organoids originate with 2D cultures of PSCs that are grown into aggregates/spheroids.At this point,they may be embedded i
40、n an extracellular matrix and expanded to maturity using a growth factor-rich media specific to the tissue of interest.The composition and organisation of cells within organoids are dictated by the identity of the tissue being grown,which,in turn,affects the overall size and shape of the organoid.It
41、 is obvious that organoid systems are already being widely and productively used in a variety of clinical and fundamental research situations,and it is only natural that the infectious diseases community would take notice.Sources:Lakobachvili et al(2017).Frontiers in Microbiology.Human Organoid Syst
42、ems by Tissue of OriginDeep Pharma Intelligence14AdSC-derivedPSC-derivedCancer biobankDisease modelingNote:The table provides information on the type(either pluripotent stem cell(PSC)-derived or adult stem cell(AdSC)-derived),biobanking status,and uses in disease modeling of the human organoid syste
43、ms reported to date,summarised by organ.PSC-derived organoids are available for all mentioned human organs.AdSC-derived human organoids have also become widely available.They have been generated from almost all endoderm-derived tissues and from gender-specific tissues.BrainOptic cupThyroidLungBlood
44、vesselMammary glandKidneyLiverStomachIntestineBladder,prostateSources:Kim et al(2020).Nature ReviewsRise of Organoids DevelopmentDeep Pharma Intelligence15Total Scientific Interest in Organoid DevelopmentNumber of Patents for OrganoidsPredicted data to the end of 2022Broadly speaking,scientific inte
45、rest in organoids development growths through the years.More recent advances in stem cell biology,combined with decades of fundamental biological studies in cell signaling and biomechanics,have accelerated the development of organoids.Over a decade,the annual publishing has grown more than 2.5 fold
46、and is expected to continue increasing.For the last decade,the growth of the number of projects working on organoids development has increased.In 2010-2022,the number of registered patents reached 7,244.This quantification includes only granted patents.Such continuous growth,driven by the huge marke
47、t potential,was made possible by the concomitant diffusion of multidisciplinary approaches.Sources:PubM,Organoids:Key PlayersDeep Pharma Intelligence16Key ProvidersKey R&D CentersKey R&D CompaniesNote:This list was generated by database creation followed by the detailed analysis of every individual
48、use case by the quantitative and qualitative features such as organoid category complexity and development possibilities of the technology,number of similar products on the market/development pipelines,the novelty of the product,addressment of the unmet needs,etc.Growths of Organoids IndustryCumulat
49、ive Number of Companies and Total Value of Their Funds,2010-2022R&D(35%)Providers(65%)The organoid market growth significantly over the last 10 years.The share of new companies from the 2010 to 2020 period is 64%.Organoids development market is valued at approximately$1,031,384 million in Q4 2022.Gr
50、owth in the historic period(from 2010 to 2022)in the organoids market resulted from the increase in investments in organoids development,growth in research and development,a rise in public-private partnerships,increased healthcare expenditure,and rising pharmaceutical R&D expenditure.Distribution of
51、 Organoid Companies by TypeTotal FundsTotal Number of CompaniesDeep Pharma Intelligence17Organoids:Key StudyDeep Pharma Intelligence18HUB Organoids(Hubrecht Organoid Technology)is the global leader in the field of adult stem cell-derived organoids based in the Netherlands.HUB Organoid Technology is
52、based on the ground-breaking discovery of Lgr5+stem cells in the adult intestine by Hans Clevers lab,which subsequently led to the development of the first mini-gut in a dish.HUB Organoid Technology does not require reprogramming or transformation of stem cells,therefore,enabling the development of
53、diseased,as well as healthy organoids,which preserve the original tissue genetic and epigenetic makeup,including clinically-relevant mutations.Lgr5+adult stem cellsHUB OrganoidsIn vitro drug testingSafety studiesDiseases model developmentOrganoid characterisationBiobankClinical trialsPreclinical tri
54、alsAssay developmentServicesThe technology captures both disease biology and the patient-specific(epi)genetic phenotype.Therefore,for the first time,a preclinical model directly represents the treatment outcome that can be expected in the patient in the clinic.Sources:huborganoids.nlClinical Trials
55、Based on OrganoidsDeep Pharma Intelligence19Clinical Trials Based on Organoids by Type of CancerWe found 72 registered clinical trials that study the potential use of organoids for drug development.On this pie chart,you can see a distribution of these clinical trials based on the therapeutic area.As
56、 expected,the most popular area is oncology and 80.5%of clinical trials are focused on the development of organoids for cancer treatment.Digestive system diseases are in the second place and 6.5%of clinical trials develop intestinal and gut organoids.All other areas are much less frequent.Clinical T
57、rials Based on Organoids by Therapeutic AreaOncologyDigestive system diseasesAllergy and ImmunologyInflammatoryVirologyInfertilityOther80,5%6,5%3,9%3,9%On this graph you can see distribution of registered clinical trials by type of cancer for which organoids are developed.The most frequent are pancr
58、eatic organoids and 12 clinical trials are developed them for studying pancreatic cancer.There are eight,seven and six clinical trials for studying lung,rectal and breast cancer respectively.Five clinical trials were registered for developing organoids to treat tumors.All other types of cancer are l
59、ess frequent.Sources:Clinicaltrials.govLongevity.InternationalOrgan-on-a-ChipUtility of Organ-on-a-Chip ModelsDeep Pharma Intelligence21Disease Pathophysiology+Toxicology+Drug action mechanism+Drug screening+Drug discovery+Therapy assay+ACADEMIAINDUSTRYCLINICSMedical LandscapeBasic Science ResearchT
60、arget Pharmacology,BiomarkerdDevelopmentLead Identificationand OptimisationCandidateSelection,INDStudies,Scale-upClinicalResearch andDevelopmentRegulatoryReviewPostmarketingThe table below lists the major(technical and biological)uses of organ-on-a-chip in academia and industry,as well as the traits
61、 that should be present for them to be successful in the clinic.Numerous other uses and distinguishing characteristics could not be included in the list of applications and attributes.The tables+symbols,with+representing the greatest value,indicate the significance of each use in research,business,a
62、nd clinical settings.These dynamic maps provide a framework for understanding modern drug development.Blue components reflect the organ-on-a-chips known current use or soon anticipated future utility,while red components show both the potential and expected utility in this schematic surrounded by se
63、veral drug development phases and processes.The basic science research stage is where many organ-on-a-chip are right now.Sources:Lucie et al(2020).Nature Reviews.Organ-on-a-Chip DiversityDeep Pharma Intelligence22Lung-on-a-ChipGut-on-a-ChipRetina-on-a-ChipPancreas-on-a-ChipBrain-on-a-ChipKidney-on-a
64、-ChipLiver-on-a-ChipArtery-on-a-ChipHeart-on-a-ChipNerve-on-a-ChipOrgan-on-a-ChipGrowths of Organ-on-a-Chip IndustryCumulative Number of Companies and Total Value of Their Funds,2010-2022R&D(18%)Providers(82%)Organ-on-a-hip market was developed equally during the last 10 years.However,in the past 2
65、years,the market has been showing increased stagnation.The share of new companies from 2010 to 2020 is 60%.The market is valued at approximately$851,26 million in Q4 2022.Some 82%of the companies are related to Providers,and only 18%are involved in R&D.Distribution of Organoid Companies by TypeTotal
66、 Number of CompaniesDeep Pharma Intelligence23Total FundsCancer-on-a-Chip PlatformsDeep Pharma Intelligence24Key CompaniesThe World Health Organization lists cancer as one of the main causes of death globally.The evaluation of new anticancer medications impact on cells must be done in a high through
67、put,cost-and time-efficient manner.The innovative cancer-on-a-chip technique,which combines microfluidics and 3D cancer models,overcomes this difficulty.It is a promising technique that can be used for drug screening,as well as to examine events like the genesis and spread of metastasis.It is also a
68、 promising tool for better simulating the cancer environment encountered in vivo.Sources:Goncalves et al(2022).Cancers.Multi-Organ-on-a-ChipFor each application(right side),a minimal set of organs necessary to build an accurate systemic model is indicated,those organs being highlighted with colored
69、squares(left side).Deep Pharma Intelligence25Multiple organ interactions are necessary to guarantee the human body is able to function physiologically.Although organs are physically separated in vivo,communication between them is maintained through a variety of signals(soluble substances,exosomes,ce
70、lls,etc.)through the blood and lymphatic circulation.Cross-organ communication and a systemic dimension must be included,as shown in figure,and this is most frequently accomplished by employing animal models.In a significant recent development,a multiorgan platform that models numerous organs in a s
71、ingle device has been created.Several companies like Hesperos,TissUse,and CN Bio create the entire human body-on-a-chip or multiple-organ-on-a-chip platforms.Sources:Picollet-Dhahan et al(2021).Trends in Biotechnology.Organ-on-a-hip:Key StudyDeep Pharma Intelligence26Deep Pharma Intelligence26Hesper
72、os,Inc.is a leader in efforts to characterise an individuals biology with Human-on-a-Chip microfluidic systems.With a mission to revolutionise toxicology testing,as well as efficacy evaluation for drug discovery,the company has created pumpless platforms with serum-free cellular mediums that allow m
73、ulti-organ system communication and integrated computational PKPD modeling of live physiological responses utilising functional readouts from neurons,cardiac,muscle,barrier tissues,and neuromuscular junctions,as well as responses from liver,pancreas,and barrier tissues.2 OrganBase efficacy and toxic
74、ity models3 OrganA more complete view of the human body4 OrganMost advanced standard system2-5 Organ+Reconfigure the platform to include the relevant organ tissues for your application.Heart-LiverAn effective test of the acute and chronic effects on the heart and liver.Heart-Liver-CancerNeuromuscula
75、r JunctionBetter understand disorders impacting the connection between the nervous and muscular systems,such as ALS.Understand the effects of both single and multidrug treatments.Heart-Liver-SkinEvaluate the safety and efficacy of topically applied products.Heart-Liver-Neuron-MuscleBetter understand
76、 the mechanisms of neurodegenerative diseases in our most advanced standard system.The platform can be easily configured to include virtually any organ,barrier tissue,or tumor.CustomisedBarrier Tissue ModulesAdding these modules to the HoaC systems enables determination of transport characteristics
77、of novel compounds as well as their responses as toxicity targets.Sources:Total Scientific Interest in Organ-on-a-Chip DevelopmentDeep Pharma Intelligence27Research on organ-on-a-chip technology has grown exponentially during the last 10 years.Explanations of such growth are dramatic advances in the
78、 sophistication of biology and engineering,in the demonstration of physiological relevance,and in the range of applications.According to PubMed,the most popular types of organ-on-a-chip are vascular system,liver,and digestive system.Among pathophysiological models,the most popular are models of canc
79、er,inflammatory,cardiovascular,and respiratory diseases.Number of PublicationsNumber of PublicationsType of Organ Type of Pathophysiological Model Sources:PubMLongevity.InternationalMicrofluidicsMicrofluidics:Main DevelopersDeep Pharma Intelligence29Microfluidics relates to the design and study of d
80、evices that move or analyse the tiny amount of liquid smaller than a droplet.Microfluidic devices have microchannels,ranging from submicron to few millimeters.Microfluidics has been increasingly used in the biological sciences because precise and controlled experiments can be conducted at a lower co
81、st and faster pace.What is Microfluidics?How do Microfluidics work?Microfluidics systems work by using a pump and a chip.Different types of pumps precisely move liquid inside the chip with a rate of 1 L/min to 10,000 L/min.For comparison,a small water drop is 10 microliter(L).Microfluidic channels l
82、ocated inside the chip allow the liquid to be processed through mixing,chemical,or physical reactions.Small particles like cells or nanoparticles may be carried by the liquid.The microfluidic device makes it possible to process these particles,for instance,by capturing and collecting cancer cells fr
83、om healthy blood cells.Main developersMicrofluidics:Usage in Drug DevelopmentMicrofluidics for Drug SynthesisMicrofluidics for Drug ScreeningMicrofluidics for Drug DeliveryMicrofluidics for Drug EvaluationCompound GenerationMicrochannel reactorsSingle-step transformationMultistep transformationsDrop
84、let microplatesIn enclosed channelIn the open environmentPreliminary Drug ScreeningContinuous-flow screeningSuccessive droplet screeningDroplet array screeningMicrofluidic Micropumps for Direct Drug DeliveryPowered micropumpsNonpowered micropumps Microfluidic Fabrication of Drug CarriesEmulsionsMicr
85、oparticlesMicrocapsulesMicrofibersSafety&Efficacy Microfluidic single-cell platformMicrofluidic cell spheroids platformMicrofluidic organ-on-a-chip platformSingle-ogan-on-a-chipMulti-organ-on-a-chipDrug synthesis,drug distribution,and drug evaluation are the three primary components of the protracte
86、d process of developing new drugs.Microfluidics has emerged as a ground-breaking technique as compared to conventional drug development methods,because it provides a highly controlled,compact environment for bio(chemical)interactions to occur.It is also compatible with analytical strategies to imple
87、ment integrated and high-throughput screening and evaluations.Deep Pharma Intelligence30Sources:Liu et al(2021).ACS PublicationsLongevity.InternationalLab AutomationLab Automation:Usage in Drug DevelopmentTime and Resources Optimisation Save a lot of time and ensure their skills are used for other m
88、ore specialised tasks.Reduced CostsEfficiency and FlexibilityLaboratory automation systems can be customised to meet a given laboratorys needs.Reduced Human ErrorOutput data can be streamed directly into electronic laboratory notebook,which minimises the risk of human errors.Maximise Data GeneratedA
89、utomation can produce extra data that are not usually collected.Benefits of Lab AutomationAutomation has enabled large-scale testing.It has also reduced utilities and equipment costs.As technology has advanced,there are more opportunities to automate procedures in the lab.Automated equipment can be
90、used throughout the entire workflow and is a vital part of many laboratories nowadays.Automation now includes integrating the laboratory environment to provide more precision and improve the correctness of outcomes in R&D,going beyond high throughput alone.Pre-analytical,analytical,and postanalytica
91、l stages can be distinguished in laboratory automation.Pre-analytical errors are thought to be responsible for more than two-thirds of all laboratory errors.Mistakes in the analytical phase and post-analytical phase account for one-third of all laboratory errors.Deep Pharma Intelligence32Main Develo
92、pers of Lab Automation Services Liquid HandlingElectronic Lab ManagementDeep Pharma Intelligence33Automated Sample StorageSample PreparationQuality ControlRobotics HardwareMultiplex AnalysisNote:This slide represents the main developers on the market of Lab automation services.It is evident that liq
93、uid handling is the most popular type of lab automation services due to its demand and prevalence.Other fields are actively growing for now.Growth of Lab Automation IndustryDeep Pharma Intelligence34Cumulative Number of Companies and Total Value of Their Funds,2010-2022R&D(30%)Providers(70%)Lab auto
94、mation market was developing equally during last 10 years.However,during the last 2 years,the market shows increased stagnation.The share of new companies from the 2010 to 2020 period is 30%.The market is valued at approximately$23.44 billion in Q4 2022.Some 70%of the companies are related to Provid
95、ers,and only 30%are involved in R&D.Distribution of Lab Automation Companies by TypeTotal Number of CompaniesTotal FundsMarket OverviewMarket at a Glance:CompaniesDistribution of Companies by Country,%USA45.5%Canada4.8%Asia10.3%Australia0.6%Distribution of Companies by Category,%The vast majority of
96、 companies that conduct preclinical and clinical optimisation services is located in Europe and accounts for 49%of the whole range of analysed companies.The European region is followed by the United States,with the total companies amounting to 45.5%of all companies in both regions.The main domains i
97、n which companies are being conducted are Organoids,Lab automation,Organ-on-a-chip,and Microfluidics,which account for 36.47%,30%,26.47%,and 7.06%of all companies,respectively.Europe49%UK9.1%Deep Pharma Intelligence36Market at a Glance:InvestorsDeep Pharma Intelligence37More than half of the investo
98、rs in preclinical and clinical optimisation companies are from the United States(around 55%).Some 11%of investors are located in the UK;6%of the investors are located in China;4%in Canada,Switzerland,and the Netherlands each.Germany,France,Belgium,and Hong Kong each host 3%of all investors.Overall,t
99、he first 10 countries by number of investors locate 87%of all investors.South Korea1 Hong Kong7 Japan1 China17 Singapore7UK31 11 11Italy4 Belgium6 Germany7US150 Canada12 Sweden5 France9SwitzerlandNetherlandsKey TakeawaysDeep Pharma Intelligence38Only one in 10 medications will pass Phase I clinical
100、trials and receive FDA approval,demonstrating the inefficiency of the drug-discovery process.In light of this,medication makers have continued to use cutting-edge new technology to maximise their efforts in drug discovery and development.Technology advancements in areas like in silico modeling,high
101、content imaging,and multiparametric analysis(using methods like impedance and kinetic-based measurements,for example)have made it possible to make more exact and nuanced discoveries at a deeper level of biology.Three-dimensional(3D)in vitro models in the drug development pipeline can help selecting
102、the most promising and safe drug candidates prior to clinical trials,reducing and sometimes even replacing animal studies.Additionally,the creation of 3D organoids from patient-derived cells has created new pathways towards a personalised medical strategy.Advances in 3D tissue models have yielded ne
103、w approaches,such as organ-on-a-chip systems.To help biopharmaceutical R&D in important therapeutic areas,manufacturers of 3D tissue models are utilising high-fidelity biology inside specialised disease model systems.Beyond drug screening,3D models have potential for new drug target discovery,accele
104、rated drug design,and the identification of trial populations for Personalised Medicine.As 3D models gain popularity,biopharma companies and enablers must address a number of issues.There is also an increased development of lab automation developers that can potentially simplify R&D studies.38Overvi
105、ew of Proprietary Analytics by Deep Pharma Intelligence40Deep Pharma IntelligenceDeep Pharma Intelligence New Era in Pharma Analytics Deep Pharma Intelligence(DPI),an analytical subsidiary of Deep Knowledge Group,is a highly specialised think tank in the area of BioTech innovation profiling,market i
106、ntelligence,and BioTech development advisory.The company is dedicated to producing powerful data mining and visualisation systems,interactive analytics tools,and industry reports,offering deep technical insights,market intelligence,and strategic guidance in the high growth and significant opportunit
107、y areas.DPI is Focusing on Three Key Activities:Conducting Market IntelligenceCreating Big Data Analytical DashboardsProducing Scientific ContentProducing regular open-access and proprietary reports on the emerging topics and trends in the pharmaceutical and healthcare industries.All reports are sup
108、ported by our back-end analytics systems and tools that allow to receive fresh insights and updates about opportunities and risks.Building a comprehensive Big Data Analytical Dashboard(SaaS)as a one-stop-platform for all market and business intelligence operations our customers may need,including pr
109、ofiling thousands of companies,market signals and trends based on tens of millions of constantly updated data points.DPI provides a full-cycle development of articles,scientific journals,and books.We are ready to develop a detailed Requirement Specifications document,including layout of the journal,
110、fully designed brand book,with example templates for each chapter.41Deep Pharma IntelligenceAI in Drug Discovery Analytical DashboardMarket Intelligence Focus AI in Drug Discovery Analytical Dashboard is a fundamental tool for strategic insights,opportunity evaluation,competitor profiling,and other
111、purposes relevant to Pharma and BioTech decision-makers,life science investors,consulting companies,and regulatory agencies.600Companies120Clinical Trials1,100Investors290R&D CollaborationsAutomated SWOT AnalysisStock Price ForecastingInteractive Chart BuilderAutomated Competitive AnalysisFinancial
112、Portfolio ConstructorMatching Tool for Investors170Parameters of Automated SWOT Analysis42Deep Pharma IntelligenceComprehensive Market IntelligenceDeep Pharma Intelligences proprietary services include custom consulting projects based on the specific customer needs,as well as a collection of preprod
113、uced ready-to-use proprietary reports,developed by our research team and covering general trends and specific action ideas and strategy insights related to the most promising business prospects(e.g.new technologies,BioTech start-ups),M&A prospects(e.g.pipeline development targets),and strategic grow
114、th ideas(trends profiling,industry overviews,etc.).Selected Open Access ReportsArtificial Intelligence for Drug Discovery Landscape Overview,Q3 2022 is an analytical report that aims to provide a comprehensive overview of the AI in drug discovery industry,clinical research,and other aspects of pharm
115、aceutical R&D.Epigenetic Drugs Q2 2022 report aims to provide a comprehensive overview of the current state of the epigenetic drugs market and research.The aim of this report is to provide insights into the diversity of possible epigenetic targets,mechanisms of their action in treating cancer and ot
116、her diseases.Landscape of Advanced Technology Companies in Pharmaceutical Industry Q4 2021 is an analytical report providing insights into the expansion of technology developers and vendors in the pharmaceutical space,as well as their increasing role in the pharmaceutical business.43Deep Pharma Inte
117、lligenceBusiness Consulting ServicesDeep Pharma Intelligence offers a comprehensive range of consulting services,including market and competitor research,technology scouting and due diligence,investment landscape profiling,and comprehensive analytics support for investment decision-making.Investment
118、 Landscape ProfilingIdentifying investment trends in the pharma,BioTech,medicine,healthcare,drug development technological space,investments risk profiling based on risk tolerance,risk capacity,and risk requirements.Market ResearchThorough market assessment within a specific industry in the field of
119、 pharma,BioTech,medicine,healthcare,drug development,AI,and others.Technology Scouting and Due DiligenceIdentifying,locating,and evaluating existing or developing technologies,products,services,and emerging trends.The service includes business,science and technology,intellectual property(IP)profilin
120、g,and potential assessment.Competitor ResearchCompetitive analysis of companies,technologies,technological sectors,etc.Competitive analysis includes SWOT analysis and competitive profiling.Deep Pharma Intelligence(DPI)Disclaimer.The information and opinions in this report were prepared by Deep Pharm
121、a Intelligence.The information herein is believed by DPI to be reliable but DPI makes no representation as to the accuracy or completeness of such information.There is no guarantee that the views and opinions expressed in this communication will come to pass.DPI may provide,may have provided or may
122、seek to provide advisory services to one or more companies mentioned herein.In addition,employees of DPI may have purchased or may purchase securities in one or more companies mentioned in this report.Opinions,estimates and analyses in this report constitute the current judgment of the author as of
123、the date of this report.They do not necessarily reflect the opinions of DPI and are subject to change without notice.DPI has no obligation to update,modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein,or any opinion,estimate,forecast or anal
124、ysis set forth herein,changes or subsequently becomes inaccurate.This report is provided for informational purposes only.It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.E-mail:infodeep-pharma.techWebsite:www.deep-pharma.techLink to the Report:www.deep-pharma.tech/clinical-trials-q4-2022